CRISPR-Cas9 Screens Agree on Genes Critical to Cancer’s Survival
CRISPR-Cas9 datasets analysis leads to largest genetic screen resource for cancer research
Related Articles
Turning Forestry Waste into Biopharmaceuticals
For some trees, wasted bark is a potential treasure-trove of biopharmaceuticals—from anti-inflammatories to cancer-fighting drugs.
Barcelona’s Blood and Tissue Bank Looks to Improve Cell Therapy Cost Effectiveness
Barcelona’s blood and tissue bank says it has developed a new system for the large-scale production of mesenchymal stromal cells.
Personalized mRNA Meds Driving Demand for Small-Scale Production
The ability to make patient-specific products quickly fits with the needs of smaller, resource-limited developers.
BIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo Proteins
This week’s episode covers a wide range of topics including an on-location update from BIO 2025 and the latest in AI news.
King Faisal Specialist Hospital & Research Center and Germfree Labs Agree to Develop Advanced Therapy Manufacturing Campus in Riyadh
The facility will be built to meet SFDA, FDA, EMA, and BMBL requirements and will include a fully integrated digital manufacturing platform.
Agenus and Noetik Collaboration Will Predict Cancer Biomarkers Using the Virtual Cell
Noetik will use its multimodal AI models to identify which patients will most likely benefit from Agenus’s lead immuno-oncology combination, BOT/BAL.
At BIO, Companies Launch New Products for AAV Manufacturing, AI Drug Discovery
Two biotech innovators launched products that solve challenges in gene therapy scale-up and learn from omics data from animals and humans.
The Future of Biomanufacturing: AI-Driven Cell Line Development and Bioprocess Design
In this GEN webinar, Thibault Laurent, an expert in cell line development and genome engineering, shares a data-driven vision for the future of biologics production…
Nanoparticle Drug Delivery System Improves Stability and Drug Loading
When tested in a mouse model of breast cancer, the doxorubicin-loaded nanoparticles caused fewer side effects than free doxorubicin.
Making Protein Therapeutics Affordable and Accessible Using Fully-Connected Continuous Biomanufacturing
In this GEN webinar, Veerendra Kumar Reddy, PhD, will introduce Enzene’s FCCM technology and discuss how it enables affordable and accessible protein therapeutics manufacturing.